<DOC>
	<DOCNO>NCT00300885</DOCNO>
	<brief_summary>A randomize control trial compare safety efficacy carboplatin paclitaxel plus minus sorafenib chemonaive patient stage III-IV non-small cell lung cancer .</brief_summary>
	<brief_title>A Randomized Controlled Trial Comparing Safety Efficacy Carboplatin Paclitaxel Plus Minus Sorafenib ( BAY 43-9006 ) Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Stage IIIB ( effusion ) Stage IV NSCLC histology No prior chemotherapy Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Greater equal 18 year age Life expectancy least 12 week Adequate bone marrow , liver renal function Prior systemic anti cancer therapy Known brain metastasis . Patients neurological symptom undergo compute tomography ( CT ) scan/magnetic resonance imaging ( MRI ) brain exclude brain metastasis Pulmonary hemorrhage/bleeding event &gt; Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 within 4 week first dose study drug Thrombotic embolic event include Transient ischemic attack ( TIA ) within past 6 month Uncontrolled hypertension Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug Major surgery within 4 week Evidence history bleed diathesis coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>